#United States #Flow Cytometry #Quest Diagnostics #Secaucus, NJ #Myeloma

Quest Diagnostics Enhances Myeloma Treatment with New Blood Test

In a groundbreaking announcement, Quest Diagnostics, a leader in diagnostic information services, introduced a sophisticated blood test designed to detect measurable residual disease (MRD) in individuals suffering from myeloma. The Quest Flow Cytometry MRD for Myeloma leverages cutting-edge flow cytometry techniques, providing sensitivity equivalent to that of next-generation sequencing (NGS) but at a significantly lower cost. This innovation not only enhances patient care but also contributes to improved healthcare outcomes.

Dr. Yuri Fesko, Chief Medical Officer at Quest Diagnostics, emphasized the importance of this new testing method, stating, "Our test harnesses cutting-edge science to provide ultrasensitive insights from a noninvasive blood test, which can significantly improve care and add value for both patients and the healthcare system." With around 7,000 blood collection sites available nationwide, this test improves access to vital diagnostics for a broader range of patients dealing with myeloma.

Understanding Myeloma and the Need for Effective Detection

Myeloma, also known as multiple myeloma, is a malignant condition affecting plasma cells—specific white blood cells responsible for producing antibodies. According to the American Cancer Society, approximately 36,000 new myeloma cases are diagnosed annually in the United States, leading to nearly 11,000 deaths. While myeloma can currently be managed with various treatments, including chemotherapy, monitoring the levels of residual disease through methods like MRD testing is essential for tracking treatment efficacy and making informed clinical decisions.

Traditionally, MRD assessments relied on bone marrow aspirates, but this method, while effective, is invasive and can be challenging for patients. Next-generation sequencing, though more sensitive than traditional methods, is also more expensive and requires baseline samples for accurate monitoring. Quest's new test circumvents these limitations by analyzing noninvasive blood samples, making it more accessible and user-friendly for patients.

Improved Technology for Better Patient Outcomes

The newly launched Flow Cytometry MRD test employs innovative techniques that match the detection capabilities found in NGS, but it does so using simple blood samples. An added advantage of this test is its five-day specimen stability, allowing for flexibility in specimen transport rather than the usual three-day limit found in conventional flow cytometry methods. This ensures that healthcare providers can efficiently analyze specimens without compromising on accuracy or timing.

Timothy Looney, Senior Director of Immuno-Oncology at Quest Diagnostics, noted the enthusiastic response from the healthcare community at the recent American Society of Hematology (ASH) Annual Meeting where the test was introduced. He believes that the affordability, sensitivity, and sample stability of this assay will redefine treatment options and monitoring for patients with myeloma, addressing a critical need in oncology.

Applications Beyond the Clinic

Beyond its clinical applications, the Quest Flow Cytometry MRD test is anticipated to serve as a valuable tool for response monitoring in clinical trials. Given that the FDA has recently issued draft guidance on utilizing MRD as a primary endpoint in trials for multiple myeloma therapies, this innovative testing solution is well-positioned to support the evolving landscape of cancer treatment and drug approvals.

Quest Diagnostics continues to strengthen its position as a premier provider of oncology testing services. The introduction of the Flow Cytometry MRD for Myeloma complements the company's existing testing capabilities, including their Haystack MRD® test designed for solid tumor cancers. This expansive portfolio underscores the commitment of Quest Diagnostics to enhance patient outcomes through advanced diagnostic technologies.

Conclusion

As Quest Diagnostics shapes the future of cancer diagnostics, their innovative flow cytometry blood test stands out as a beacon of hope for myeloma patients and their families. By enhancing access to critical diagnostics, Quest is not only improving the quality of life for many but is also playing a significant role in advancing cancer care. As they continue their mission to deliver insightful diagnostic solutions, the impact of their latest advancements in MRD detection will undoubtedly resonate throughout the healthcare community and beyond.

For more information about Quest Diagnostics and their testing services, visit QuestDiagnostics.com.